Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
BIONOXX INC. has 6 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed across 6 examiners and 5 art units, showing a broad examiner spread with one art unit handling more than one of the actions.
CORNET, JEAN P is the busiest examiner, with 1 pending matter. No single examiner accounts for a larger recorded concentration, so prosecution management should emphasize matter-level coordination and consistent review across the separate examiner assignments. The art-unit distribution also warrants attention when identifying recurring technical or procedural issues.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (17%) |
| §103 only | 3 (50%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CORNET, JEAN P | 1 | 41.9% | +47.2% |
| BLUMEL, BENJAMIN P | 1 | 70.7% | +30.6% |
| DENT, ALANA HARRIS | 1 | 44.1% | +32.2% |
| ALAM, DANYAL HASSAN | 1 | 66.7% | +0.0% |
| EBBINGHAUS, BRIANA NOEL | 1 | 59.7% | +63.0% |
| WANG, RUIXUE | 1 | 55.9% | +19.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17638143 | PHARMACEUTICAL COMPOSITION COMPRISING VACCINIA VIRUS AND HYDROXYUREA AS ACTIVE INGREDIENT FOR TREATMENT OF CANCER | ALAM, DANYAL HASSAN | 26d |
| 16976125 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING ANTICANCER VIRUS AND HYDROXYUREA AS EFFECTIVE COMPONENTS | WANG, RUIXUE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17638144 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING ANTICANCER VIRUS, IMMUNE CHECKPOINT INHIBITOR AND HYDROXYUREA AS ACTIVE INGREDIENTS | DENT, ALANA HARRIS | 23d overdue |
| 17798131 | PHARMACEUTICAL COMPOSITION FOR INHIBITING INFLAMMATORY RESPONSE COMPRISING HYDROXYUREA | CORNET, JEAN P | — |
| 17638750 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING VACCINIA VIRUS AND GRANULOPOIESIS INHIBITOR AS ACTIVE INGREDIENTS | BLUMEL, BENJAMIN P | — |
| 17595220 | ONCOLYTIC VIRUS WITH IMPROVED SAFETY AND ANTICANCER EFFECTS | EBBINGHAUS, BRIANA NOEL | — |
| 16976125 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING ANTICANCER VIRUS AND HYDROXYUREA AS EFFECTIVE COMPONENTS | WANG, RUIXUE | — |
| Art Unit | Apps |
|---|---|
| 1671 | 2 |
| 1628 | 1 |
| 1643 | 1 |
| 1632 | 1 |
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17798131 | PHARMACEUTICAL COMPOSITION FOR INHIBITING INFLAMMATORY RESPONSE COMPRISING HYDROXYUREA | CORNET, JEAN P | 1628 | §103 | Non-Final OA | — | Pending | Aug 08, 2022 |
| 17638750 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING VACCINIA VIRUS AND GRANULOPOIESIS INHIBITOR AS ACTIVE INGREDIENTS | BLUMEL, BENJAMIN P | 1671 | §103 | Non-Final OA | — | Pending | Feb 25, 2022 |
| 17638144 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING ANTICANCER VIRUS, IMMUNE CHECKPOINT INHIBITOR AND HYDROXYUREA AS ACTIVE INGREDIENTS | DENT, ALANA HARRIS | 1643 | §103 | Non-Final OA | 23d overdue | Pending | Feb 24, 2022 |
| 17638143 | PHARMACEUTICAL COMPOSITION COMPRISING VACCINIA VIRUS AND HYDROXYUREA AS ACTIVE INGREDIENT FOR TREATMENT OF CANCER | ALAM, DANYAL HASSAN | 1671 | §101§103 | Non-Final OA | 26d | Pending | Feb 24, 2022 |
| 17595220 | ONCOLYTIC VIRUS WITH IMPROVED SAFETY AND ANTICANCER EFFECTS | EBBINGHAUS, BRIANA NOEL | 1632 | §102DP | Non-Final OA | — | Pending | Nov 11, 2021 |
| 16976125 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING ANTICANCER VIRUS AND HYDROXYUREA AS EFFECTIVE COMPONENTS | WANG, RUIXUE | 1672 | §103§112 | Non-Final OA | — | Pending | Aug 27, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBIONOXX INC. has 6 pending office actions as of October 2026, spread across 5 art units and 6 examiners.
Jean P Cornet has the most, with 1 of BIONOXX INC.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
